Standard BioTools Inc.

Equities

LAB

US34385P1084

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:01 2024-05-16 pm EDT			5-day change	1st Jan Change
2.51 ^USD	-0.79%		+4.15%	+13.57%

May. 08	Transcript : Standard BioTools Inc., Q1 2024 Earnings Call, May 08, 2024
May. 08	Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q1 Revenue $45.5M, vs. Street Est of $46M	MT

Fluidigm Corporation Announces Resignation of Colin McCracken as Chief Commercial Officer, Effective June 12, 2022

March 16, 2022 at 04:06 pm EDT

On March 10, 2022, Colin McCracken, the Chief Commercial Officer of Fluidigm Corporation notified the Company of his intention to resign, effective as of June 12, 2022, after assisting with the Company's transition plan with respect to his role and responsibilities.

Latest news about Standard BioTools Inc.

Transcript : Standard BioTools Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q1 Revenue $45.5M, vs. Street Est of $46M	May. 08	MT
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024	May. 08	CI
Standard BioTools Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Sector Update: Health Care Stocks Decline Late Afternoon	Apr. 25	MT
Sector Update: Health Care	Apr. 25	MT
Standard BioTools Initiates Restructuring Plan With 10% Workforce Reduction	Apr. 25	MT
Standard BioTools Inc. Announces Operational Restructuring Plan	Apr. 25	CI
TD Cowen Starts Standard BioTools With Buy Rating, $3.50 Price Target	Apr. 16	MT
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging	Apr. 08	CI
Jefferies Initiates Coverage on Standard BioTools With Buy Rating, $3.25 Price Target	Apr. 04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	Apr. 04	MT
Standard BioTools Enters Into Multi-Year Medicine Research Engagement With Bristol-Myers Squibb	Apr. 04	MT
Transcript : Standard BioTools Inc., Q4 2023 Earnings Call, Feb 28, 2024	Feb. 28
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024	Feb. 28	CI
Standard BioTools Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Standard BioTools Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28	CI
Earnings Flash (LAB) STANDARD BIOTOOLS Reports Q4 Revenue $28.2M, vs. Street Est of $24.9M	Feb. 28	MT
Standard BioTools Inc. and Next Gen Diagnostics Announce Partnership to Provide Complete Automation of Low-Cost Pathogen Sequencing	Feb. 26	CI
Standard Biotools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine	Feb. 07	CI
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023	Jan. 08	CI
Standard BioTools Says Merger With SomaLogic Completed	Jan. 05	MT
Standard BioTools Inc. Announces Management Changes	Jan. 05	CI
SomaLogic, Standard BioTools Receive Shareholder Approvals for Pending Merger	Jan. 05	MT
Standard BioTools Inc. completed the acquisition of SomaLogic, Inc..	Jan. 04	CI

Chart Standard BioTools Inc.

Duration

Period

More charts

Company Profile

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Standard BioTools Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.51 USD

Average target price

3.583 USD

Spread / Average Target

+42.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
STANDARD BIOTOOLS INC.	+13.57%	968M
THERMO FISHER SCIENTIFIC	+12.50%	229B
DANAHER CORPORATION	+14.52%	195B
INTUITIVE SURGICAL, INC.	+17.51%	142B
BOSTON SCIENTIFIC CORPORATION	+28.96%	109B
SIEMENS HEALTHINEERS AG	+3.27%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+18.16%	54.33B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.63%	52.09B
AGILENT TECHNOLOGIES, INC.	+10.95%	45.15B
GE HEALTHCARE TECHNOLOGIES INC.	+5.10%	37.39B

Other Advanced Medical Equipment & Technology